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Summary
Barth syndrome (BTHS) is an X-linked recessive disease primarily affecting males. Clinically, the disease is characterized
by hypertrophic or dilated cardiomyopathy, skeletal myopathy, chronic/cyclic neutropenia, 3-methylglutaconic aciduria,
growth retardation and respiratory chain dysfunction. It is caused by mutations in the TAZ gene coding for the tafazzin
protein which is responsible for cardiolipin remodeling. In this work, we present a novel pathogenic TAZ mutation
c.83T>A, p.Val28Glu, found in mosaic form in almost all female members of a Polish family. Sanger sequencing of DNA
from peripheral blood and from epithelial cells showed female mosaicism in three generations. This appears to be a new
mechanism of inheritance and further research is required in order to understand the mechanism of this mosaicism. We
conclude that BTHS genetic testing should include two or more tissues for women that appear to be noncarriers when
blood DNA is initially tested. The results of our study should not only be applicable to BTHS families, but also to families
with other X-linked diseases.
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Introduction
Barth syndrome (BTHS, OMIM 302060) is a rare lipid
metabolism disorder first described in 1983 by Barth et al.
(Barth et al., 1983; Bione et al., 1996). It is an X-linked reces-
sive inherited disease. Typically, it is characterized by hyper-
trophic or dilated cardiomyopathy (CMP), skeletal myopathy,
chronic or cyclic neutropenia, 3-methylglutaconic aciduria,
as well as growth retardation and respiratory chain dysfunc-
tion (Chitayat et al., 1992; Christodoulou et al., 1994; Besley
et al., 1995; Barth et al., 2004; Spencer et al., 2006). Inci-
dence of BTHS has been estimated as 1 in 300,000–400,000
in the United States and 1 in 140,000 in the United Kingdom,
although more accurate incidence is not known and it seems
to be an underdiagnosed condition (Barth Syndrome Foun-
dation: http://www.barthsyndrome.org/home; Clarke et al.,
2013). Laboratory testing to confirm the clinical diagnosis is
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based on urinary 3-methylglutaconic acid (3-MGCA) testing,
monolysocardiolipin/cardiolipin(MLCL:L4-CL) ratio testing
and tafazzin gene (TAZ, previously termed G4.5) sequenc-
ing (especially when CL testing is not available; Clarke et al.,
2013).
BTHS is caused by various mutations in the TAZ gene,
located in region Xq28; it contains 11 short exons and
10 introns (Barth et al., 1983; Bolhuis et al., 1991; Bione
et al., 1996; Gonzalez, 2005; Spencer et al., 2006; Arad-
hya et al., 2012). This 10,966 base pair-long gene encodes
taffazin – phospholipid-lysophospholipid transacylase protein
with phospholipid acyltransferase function. Taffazin plays an
important role in remodeling of CL and phosphatidylglycerol
structure (Barth et al., 1983).
CL is a component of the inner mitochondrial membrane
and is involved in the mitochondrial electron transport chain
(Raja & Greenberg, 2014), playing an essential role in cellular
energy metabolism, mitochondrial dynamics and the incep-
tion of apoptotic pathways (Raja & Greenberg, 2014). It was
demonstrated that the loss of CL in the inner mitochon-
drial membrane results in respiratory chain dysfunction, most
specifically of complexes I, III and IV (Barth et al., 2004;
Brandner et al., 2005; McKenzie et al., 2006). To date, more
than 150 different TAZ gene mutations have been identified
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Novel TAZ Gene Mutation and Inherited Mosaicism
in patients with diagnosed BTHS [Human Tafazzin (TAZ)
Gene Mutation and Variation Database, last updated August
18, 2014].
In this paper, we report a novel mutation in exon 1 of the
TAZ gene and female mosaicism in three generations of a




The boy was the second child of a mother with family
history of genetically inherited CMP. At 4 months of age,
the proband was admitted to hospital due to heart failure
signs: diarrhea preceded by feeding difficulties, cardiovascu-
lar instability, dyspnea, poor peripheral perfusion and neu-
tropenia. On physical examination, loud systolic murmur in
the whole precordium was found. Echocardiographic eval-
uation showed dilated CMP with EF 30%. Subsequently,
the child experienced septic shock after staphylococcal in-
fection. Cardiac function did not normalize and the patient
presented numerous episodes of severe acute heart failure.
Consequently, an inborn error of metabolism and genetic test-
ing were considered. Biochemical investigations based on gas
chromatography–mass spectrometry showed the absence of
3-methylglutaconic aciduria and presence of a small amount
of p-hydroxyphenyllactic acid and p-hydroxyphenylpyruvic
acid in urine. Blood samples were collected to perform ge-
netic testing. The boy suddenly died at the age of 6 months.
The mother’s family history led to suspicion of inherited
CMP, specifically BTHS, based on two males: the 10-year-
old son of the proband’s aunt (IV-3) had CMP and has had
a cardiac transplantation. In addition, a cousin’s brother died
suddenly at 3 weeks (IV-6).
In order to confirm the speculated clinical diagnosis of the
proband, his parents, sister and grandmother were included in
a molecular genetics study. Additional molecular analysis of
the proband’s male and female cousins, the mother`s cousins
and their grandmother was performed. A detailed pedigree of
the family was constructed (Fig. 1).
Molecular Genetic Studies
Total genomic DNA was isolated from peripheral blood
cells and from buccal swab epithelial cells. Isolation was
performed with High Pure PCR Template Preparation Kit
(ROCHE Diagnostic, Mannheim, Germany). Sequences
of primers specific to the TAZ gene were according to
Johnston et al. and Vessel et al., as previously described
(Johnston et al., 1997; Vesel et al., 2003). The 11 TAZ
coding exons and adjacent intronic regions were amplified by
PCR with FastStart PCR Master Kit (ROCHE Diagnostic).
The sequences were determined on both DNA strands from
at least two independent PCR products. The PCR products
were purified with High Pure PCR Product Purification
Kit (ROCHE Diagnostic) and sequenced with BigDye
Terminator v.3.1 Cycle Sequencing Kit (Life Technologies,
Foster City, CA, USA). The products of cycle sequencing
were purified of unbound fluorescent dyes with BigDye
XTerminator Purification Kit (Life Technologies, Foster City,
CA, USA) and separated on the 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). The sequences
were analyzed by using AB DNA Sequencing Analysis Soft-
ware v.5.2. (Applied Biosystems) and then were compared
to the TAZ gene reference (NCBI GeneBank Reference Se-
quence Accession Numbers: NM_000116.3 and ENSEMBL
database Accession Numbers: ENST00000299328).
Ethics statement
Informed consent was obtained from all family members.
Results
Mutation Analysis
A hemizygous c.83T>A substitution in TAZ exon 1 was
found in peripheral blood DNA of the proband (IV-1). The
mutation is predicted to result in the replacement of valine
with glutamic acid (p.Val28Glu) in tafazzin. The mutation
was not detected in the mother’s (III-1) peripheral blood cell
DNA, but was found in heterozygous form in DNA extracted
from epithelial cells.
The maternal grandmother (II-1) of the patient is het-
erozygous for c.83T>A in peripheral blood cell DNA and in
epithelial cell DNA. In the proband’s sister (IV-2), the muta-
tion was present neither in the peripheral blood nor in DNA
from epithelial cells.
The proband’s cousin (IV-3), who is affected with CMP,
also carries the hemizygous mutation c.83T>A in both blood
and epithelial cell DNA. Blood cell DNA from the mother
(III-2) of this boy shows only traces of heterozygosity for
the c.83T>A mutation, perhaps indicating a percentage of
mosaicism in that tissue; DNA from her epithelial cells is
clearly heterozygous at c.83. The boy’s grandmother (II-2) is
heterozygous for c.83T>A in epithelial but not in blood cells.
With regard to other family members, the proband’s aunt
(III-3, cousin of his mother) is heterozygous for c.83T>A
only in DNA from epithelial cells, and her daughters (IV-5
and IV-6) also show heterozygosity in epithelial cells, but not
in peripheral blood DNA. Heterozygosity for c.83T>A was
also observed in the maternal grandmother (II-2).
Family pedigree is shown in Figure 2.
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Figure 1 The pedigree of the family. The proband is indicated by the black arrow. Symbol with question mark “?” indicates an
individual who did not have clinical evaluation and genetic testing. The blood and epithelial mutation status is described for each
female carrier.
Discussion
We have found the novel exon 1 TAZ substitution c.83T>A
(p.Val28Glu) in 10 members belonging to three generations
of a Polish family.
This mutation has not been previously reported in the Hu-
man TAZ Gene Mutation and Variation Database (latest up-
date August, 2014; http://www.barthsyndrome.org/home).
A deletion of the entire codon (c. 82_84delGTG) is the
only variant reported in this database for position Valine 28.
In order to confirm whether the detected missense vari-
ant affects protein function, analysis using two programs, Sort-
ing Intolerant From Tolerant (SIFT; http://sift.bii.a-star.edu.
sg/www/SIFT_intersect_coding_submit.html) and Poly-
morphism Phenotyping v2 (PolyPhen-2; http://genetics.
bwh.harvard.edu/pph2/) was conducted. This analysis sup-
ported the deleterious character of this mutation showing the
PROVEAN score -5,670 (http://sift.bii.a-star.edu.sg/www/
SIFT_intersect_coding_submit.html). Additionally, it was
confirmed that the identified TAZ gene mutation occurs in
the first exon, which is highly conserved between species
(Landau et al., 2005). The position of 28Val in tafazzin
shows a high degree of conservation in vertebrates and
in arthropod invertebrates (Fig. 3; NCBI HomoloGene:
https://www.ncbi.nlm.nih.gov/homologene; Edgar, 2004).
Amino acid sequence conservation is very high for tafazzin.
Comparison of the human tafazzin sequence to Macaca mu-
latta shows 98.5% conservation, 91.5% conservation com-
pared to Canis lupus familiaris, 97.3% compared to Bos Taurus,
97.3% and 96.9%, respectively, to Mus musculus and Rattus
norvegicus (NCBI HomoloGene: https://www.ncbi.nlm.nih.
gov/homologene). Mutations which occur at positions that
are conserved throughout evolution are more likely to be
disease-causing (Ng & Henikoff, 2006). Analysis with the Al-
ternative Splice Site Prediction (ASSP) program showed a loss
of constitutive donor splice site in the presence of mutation
c.83 T>A suggesting that this disruption of constitutive splic-
ing may results in loss of gene expression (Faustino & Cooper,
2003). This hypothesis could be confirmed by testing the
mRNA of affected male (IV-3) to see if it is mis-spliced.
Our proband as well as his male cousin affected with CMP
manifested a wide range of clinical features typically asso-
ciated with BTHS and originally described by Barth et al.
(1983), which confirms that this newly discovered mutation
p.Val28Glu is a mutation strongly affecting the normal func-
tion of the Taffazin protein and thus is pathogenic.
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Figure 2 TAZ sequencing electropherograms
showing position 83 of the coding DNA sequence
(indicated by the red frame). (A) The results in the
proband, his mother, sister and maternal
grandmother. (B) The TAZ gene sequences of
proband’s cousins with CMP, his mother and
maternal grandmother. (C) Results in other family
members: proband’s aunt, her two daughters and
their maternal grandmother.
Figure 3 Multiple sequence alignment of the TAZ protein. We
show the fragment of tafazzin between amino acids 15 and 48 in
homosapiens and in other species. Alignment was generated by
MUSCLE version 3.6. A Valine at amino acid position 28 is
highlighted in gray. Identical amino acids are highlighted in black.
Tafazzin, the BTHS gene, encodes a MLCL transacylase
that is the major contributor to the final acyl chain compo-
sition of mature CL (Bione et al., 1996; Xu et al., 2006).
The process of CL acyl chain remodeling involves three dis-
tinct pathways, one of which is specifically affected in patients
affected by Barth syndrome (Schlame & Ren, 2006). The im-
portance of Valine at position 28 of tafazzin is supported by the
CL deficiency observed in the individual with the p.Val28del
mutation reported in the database.
Family studies showed that the proband’s mother, mater-
nal grandmother and aunt, as well as the male and female
cousins, carry the same mutation. In addition, our analysis
revealed somatic or both somatic and germline mosaicism
in this family. Genetic mosaics are organisms having two or
more genetically distinct populations of cells resulting from
fertilization of one egg (Strachan & Read, 1999). Mosaicism
can be tissue-specific or tissue-limited (Biesecker & Spinner,
2013) which is why we performed genetic testing of two dif-
ferent somatic tissues (mesoderm-derived lymphocytes and
ectoderm-derived buccal epithelial cells). At the moment,
there is only one scientific report on the occurrence of mo-
saicism in Barth syndrome (Chang et al., 2010) but many
on the presence of different mosaicism types in other genetic
diseases coupled with the X or autosomal chromosomes have
been reported (Bakker et al., 1987; Puck et al., 1995; Forissier
et al., 2000; Barbosa et al., 2008; Chiang et al., 2009; Alsina
et al., 2013; Borgulova´ et al., 2013; Dufendach et al., 2013).
In this family, it was found that the mutation p.Val28Glu is
present in ectodermal as well as in mesodermal cells in the
proband’s grandmother and male cousin, whereas in samples
taken from the proband’s mother and aunts the mutation is
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present only in mesodermal peripheral blood cells or at a low
level of mosaicism in ectodermal buccal epithelial cells. The
proband’s female cousins carry the same mutation and distri-
bution of mosaicism between epithelial cells and blood. On
the basis of this study, occurrence of gonosomal (gonadal and
somatic) mosaicism might be suspected. Confirmation of the
prevalence of gonadal mosaicism in women is impossible be-
cause the germline DNA is not accessible (we cannot obtain
oocytes for research; furthermore, every egg would have to be
tested). Because the father did not transmit an X chromosome
to his son, each mother must carry the TAZ mutation in her
germline. For this reason, only germline mosaicism would
be expected, although it could not be confirmed, and the
transmission rate for future pregnancies is not known. This
mutation has been passed through three generations attesting
to the fact that at least part of the germline carries the mu-
tation. We do not know if the germline is fully or partially
affected.
We suppose that the mosaicism prevalent in the family
could be inherited because it is present in different proportions
in three generations of women carriers of the genetic disease.
Genetic mosaics can result from mutations in the DNA, dif-
ferent epigenetic mechanisms, chromosomal aberrations and
spontaneous reversion of inherited mutations (Youssoufian &
Pyeritz, 2002). Further investigations, especially of the epi-
genetic processes which control cell fate, as well as parental
imprinting and X chromosome inactivation, are needed. A
mutation may arise in stem cells, during differentiation and
in terminally differentiated somatic cells (Lupski, 2013). Co-
existence of gonadal and somatic mosaicism in one person
is possible when the mutation occurs during early embryo-
genesis before differentiation to germ layers (Youssoufian &
Pyeritz, 2002). According to Zlotogora, if a germline muta-
tion occurs before meiosis, it should be present in up to 50%
of the gonadal cells (Zlotogora, 1998). Gonads can be fully
affected with mutations when they have developed from a sin-
gle mutant cell or can be partially affected if more precursor
cells are involved in gonadal differentiation (van Essen et al.,
2003). When the mosaicism is present in buccal epithelial
cells, this may indicate that the mutation is also present in the
cells derived from the ectodermal germ layer and arose only in
this germ layer but not in others (Frederiksen and Andersen,
2006). The fact that a degree of mosaicism is also present in
the blood of the proband’s grandmother and aunt (II-1, III-2)
may suggest that the mutation occurred before the division of
the three germ layers. If a mutation has been transferred from
the oocyte, all cells should have the mutation. In this family,
almost all carriers of the mutation (excluding proband’s grand-
mother (II-1), proband’s aunt (III-2) and male cousin (IV-3))
do not have the mutated cells in the blood. Mosaicism in the
somatic and/or gonadal tissues must originate at an early stage
of zygote divisions, when mutations may arise de novo. In this
case, it seems to be difficult to explain the mechanism of
formation of the mutation which is inherited between three
generations of the family. In our family, only DNA material
from two tissues has been tested, therefore it is not known
whether mosaicism also occurs in other tissues.
If an individual inherits a heterozygous mutation, present
in all somatic cells, loss of the mutation would be possible due
to a reversion mutation. Such a phenomenon might account
for the loss of the mutation in some blood cells of the female
carriers of the pedigree. However, this is an unlikely scenario
as one nucleotide in three billion would have to be targeted
in multiple individuals. An alternative would be loss of the
X chromosome carrying the mutation in the cells (making
them 45XO).
To summarize, we have presented an unusual family with
three generations of female carriers who are mosaic for a mu-
tation in the X-linked TAZ gene. This highlights a diagnostic
testing problem for potential carriers who have an affected
son: if she appears to be a noncarrier in her blood-derived
DNA, she may still be a carrier in other tissues including
the gonads. Follow-up testing should then be performed on
buccal epithelial cells or on hair follicle DNA, the most easily
accessible other tissues. For this family, genetic counseling is
difficult in the absence of an estimated transmission risk.
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